DENVER, Colo., 13 June, 2024 (247marketnews.com)- Vivani Medical, Inc. is making waves in the biopharmaceutical sector with its recent developments. The company, trading under Nasdaq symbol VANI, has seen a surge in its stock price, reaching $1.928 in the pre-market session. This bullish trend reflects a notable 20.49% increase from the previous session’s closing price, attracting substantial investor interest with a trading volume of 1.9 million shares.
In a significant breakthrough, Vivani has received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application for NPM-119, an innovative drug implant designed to address medication non-adherence and tolerability issues associated with type 2 diabetes treatments. This milestone showcases Vivani’s commitment to transforming diabetes care through sustained therapeutic delivery of exenatide over an extended period.
The company is now gearing up for the LIBERATE-1 Phase 1 clinical trial, utilizing its proprietary NanoPortal implant platform technology for the first time. This pivotal trial marks Vivani’s transition to a clinical-stage entity, poised to lead advancements in biopharmaceutical innovation and patient care.
Dr. Adam Mendelsohn, Vivani’s President and CEO, expressed optimism about NPM-119’s potential to revolutionize diabetes treatment by enhancing patient adherence and efficacy. He highlighted the importance of LIBERATE-1 in advancing the understanding of this novel therapy’s pharmacokinetics and its comparison to existing treatments.
With a robust pipeline including promising candidates like NPM-115 and NPM-139 for chronic weight management, Vivani reaffirms its dedication to driving positive patient outcomes and reshaping drug implant solutions for chronic diseases.
As Vivani accelerates its transformative initiatives, the company remains steadfast in its mission to elevate medication adherence and patient well-being. Stay updated on Vivani Medical, Inc.’s pioneering advancements by visiting the official company website for more information on its cutting-edge projects.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (VANI)
- Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
- Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
- Vivani Medical to Present at the 2025 BIO International Convention
- Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
- Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results